<?xml version="1.0" encoding="UTF-8"?><BillSummaries>
<item congress="116" measure-type="hr" measure-number="3878" measure-id="id116hr3878" originChamber="HOUSE" orig-publish-date="2019-07-23" update-date="2020-12-15">
<title>Block, Report, And Suspend Suspicious Shipments Act of 2020</title>
<summary summary-id="id116hr3878v53" currentChamber="HOUSE" update-date="2020-12-15">
<action-date>2020-11-17</action-date>
<action-desc>Passed House</action-desc>
<summary-text><![CDATA[<p><b>Block, Report, And Suspend Suspicious Shipments Act of 2020</b></p> <p>This bill creates additional requirements for drug manufacturers and distributors who discover a suspicious order for controlled substances.</p> <p>In addition to reporting the suspicious order to the Drug Enforcement Administration (DEA), a manufacturer or distributor must also exercise due diligence and decline to fill the order.</p> <p>The DEA must issue regulations specifying the indicators that give rise to a suspicious order.</p>]]></summary-text>
</summary>
<summary summary-id="id116hr3878v08" currentChamber="HOUSE" update-date="2020-11-23">
<action-date>2020-11-16</action-date>
<action-desc>Reported to House, Part I</action-desc>
<summary-text><![CDATA[<p><b>Block, Report, And Suspend Suspicious Shipments Act of 2020</b></p> <p>This bill creates additional requirements for drug manufacturers and distributors who discover a suspicious order for controlled substances.</p> <p>In addition to reporting the suspicious order to the Drug Enforcement Administration, a manufacturer or distributor must also exercise due diligence and decline to fill the order.</p>]]></summary-text>
</summary>
<summary summary-id="id116hr3878v00" currentChamber="HOUSE" update-date="2020-02-07">
<action-date>2019-07-23</action-date>
<action-desc>Introduced in House</action-desc>
<summary-text><![CDATA[<p><b>Block, Report, And Suspend Suspicious Shipments Act of 2019</b></p> <p>This bill creates additional requirements for drug manufacturers and distributors who discover a suspicious order for controlled substances. </p> <p>In addition to reporting the suspicious order to the Drug Enforcement Administration, a manufacturer or distributor must also exercise due diligence and decline to fill the order. </p>]]></summary-text>
</summary>
</item>
<dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
<dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
</dublinCore>
</BillSummaries>
